ArticleHeart and vessels2014
Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts.
Article in Heart and vessels, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Plasma Proteome Signature for Leukocyte Telomere Length and Its Link to Abdominal Aortic Aneurysm.Journal of cellular and molecular medicine · 2026Article
- Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers.International journal of molecular sciences · 2023Review
- Circulating Biomarkers in Hypertrophic Cardiomyopathy.Journal of the American Heart Association · 2022Review
- Characterization of atherosclerotic plaques in blood vessels with low oxygenated blood and blood pressure (Pulmonary trunk): role of growth differentiation factor-15 (GDF-15).BMC cardiovascular disorders · 2021Article
- Oxidative Stress and Inflammatory Markers in Abdominal Aortic Aneurysm.Antioxidants (Basel, Switzerland) · 2021Article
- Prognostic Utility of Circulating Growth Factors in Aortic Valve Stenosis: A Pilot Study.Medicina (Kaunas, Lithuania) · 2021Article
- Therapeutic and Diagnostic Value of Caspase-12 and Study of Growth Differentiation Factor-15 in Patients with Acute Myocar-dial Infarction.Iranian journal of public health · 2020Article
- Relationship of growth differentiation factor-15 with aortic stiffness in essential hypertension.Future science OA · 2019Article
- Association between Growth Differentiation Factor 15 and Non-Dipping Circadian Pattern in Patients with Newly Diagnosed Essential Hypertension.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2019Article
- Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.Archives of medical science : AMS · 2018Article
- Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy.Heart and vessels · 2017Observational
- High serum levels of thrombospondin-2 correlate with poor prognosis of patients with heart failure with preserved ejection fraction.Heart and vessels · 2016Article
- GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective.Journal of diabetes research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To distinguish hypertrophic cardiomyopathy (HCM) from hypertensive left ventricular hypertrophy (H-LVH) based on a morphological examination is often challenging. Growth differentiation factor 15 (GDF-15) is a novel diagnostic and prognostic biomarker for several cardiovascular diseases. In patients with LVH, GDF-15 promises to be a useful biomarker to distinguish between HCM and H-LVH. We evaluated 93 patients with H-LVH, 28 with HCM, and 28 disease control individuals. Serum GDF-15 concentrations were measured with an enzyme-linked immunosorbent assay. Circulating GDF-15 levels were significantly higher in patients with H-LVH than with HCM (P = 0.003). On the other hand, values for plasma B-type natriuretic peptide (BNP) levels were significantly lower in patients with H-LVH than with HCM (P = 0.004). Serum GDF-15 and plasma BNP levels positively correlated in patients with H-LVH but not with HCM. Multivariate logistic regression analysis revealed GDF-15 (odds ratio 12.06, confidence interval 1.85-78.77, P < 0.01) as an independent predictor of H-LVH among patients with LVH. In receiver-operating characteristic analysis, GDF-15 achieved an area under the curve of 0.70 for the identification of H-LVH. We found that GDF-15 might be a useful biomarker for discriminating HCM from H-LVH. Understanding serum GDF-15 values may have clinical utility for patients with LVH because the therapeutic strategies for treating HCM and H-LVH differ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.